Diffuse Large B-cell Lymphoma Research Articles

ABCL-716 Delaying Chemotherapy in Diffuse Large B-Cell Lymphoma Has No Impact in Outcomes

ABCL-716 Delaying Chemotherapy in Diffuse Large B-Cell Lymphoma Has No Impact in Outcomes

A Proposed Prognostic Score Including Circulating Free DNA (ctDNA) Concentration in Diffuse Large B-Cell Lymphoma (DLBCL): Single Centre Study

A Proposed Prognostic Score Including Circulating Free DNA (ctDNA) Concentration in Diffuse Large B-Cell Lymphoma (DLBCL): Single Centre Study

ABCL-119 Tumor CD20 Loss and Poor Outcome in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

ABCL-119 Tumor CD20 Loss and Poor Outcome in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Real-World Use of Tafasitamab for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the United States by Age Group (>70 Years and ≤70 Years)

Real-World Use of Tafasitamab for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the United States by Age Group (>70 Years and ≤70 Years)

Quantitative Systems Pharmacology Model Predicts Combination Activity of CD19-Targeted Loncastuximab Tesirine Co-Dosed With a CD20/CD3 T-Cell Bispecific (Epcoritamab) in Diffuse Large B-Cell Lymphoma

Quantitative Systems Pharmacology Model Predicts Combination Activity of CD19-Targeted Loncastuximab Tesirine Co-Dosed With a CD20/CD3 T-Cell Bispecific (Epcoritamab) in Diffuse Large B-Cell Lymphoma

Epcoritamab + R-DHAX/C Induces Deep, Durable Responses in Transplant-Eligible Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL), Including High-Risk Disease

Epcoritamab + R-DHAX/C Induces Deep, Durable Responses in Transplant-Eligible Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL), Including High-Risk Disease

ABCL-031 A Proposed Prognostic Score Including Circulating Free DNA (ctDNA) Concentration in Diffuse Large B-Cell Lymphoma (DLBCL): Single Centre Study

ABCL-031 A Proposed Prognostic Score Including Circulating Free DNA (ctDNA) Concentration in Diffuse Large B-Cell Lymphoma (DLBCL): Single Centre Study

Preliminary Safety and Efficacy Data of Combination Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Adriamycin, Prednisone (Pola-R-CHP) in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) in the Standard-of-Care Setting: A Single-Center Experience

Preliminary Safety and Efficacy Data of Combination Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Adriamycin, Prednisone (Pola-R-CHP) in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) in the Standard-of-Care Setting: A Single-Center Experience

First Data From Subcutaneous Epcoritamab + Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) for First-Line Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE NHL-5

First Data From Subcutaneous Epcoritamab + Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) for First-Line Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE NHL-5

ABCL-380 Cell-Free Circulating DNA as a Prognostic Factor for Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Hepatitis C Virus (HCV)

ABCL-380 Cell-Free Circulating DNA as a Prognostic Factor for Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Hepatitis C Virus (HCV)

Cell-Free Circulating DNA as a Prognostic Factor for Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Hepatitis C Virus (HCV)

Cell-Free Circulating DNA as a Prognostic Factor for Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Hepatitis C Virus (HCV)

ABCL-207 Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States by Primary Refractory Status

ABCL-207 Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States by Primary Refractory Status

Epcoritamab + GemOx Induces Deep, Durable Responses in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Results From EPCORE NHL-2

Epcoritamab + GemOx Induces Deep, Durable Responses in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Results From EPCORE NHL-2

Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States by Primary Refractory Status

Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States by Primary Refractory Status

ABCL-427 Polatuzumab-R-CHP in Previously Untreated Diffuse Large B-Cell Lymphoma: A Retrospective Study

ABCL-427 Polatuzumab-R-CHP in Previously Untreated Diffuse Large B-Cell Lymphoma: A Retrospective Study

ABCL-275 Epcoritamab + GemOx Induces Deep Durable Responses in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Results From EPCORE NHL-2

ABCL-275 Epcoritamab + GemOx Induces Deep Durable Responses in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Results From EPCORE NHL-2

Polatuzumab-R-CHP in Previously Untreated Diffuse Large B-Cell Lymphoma: A Retrospective Study

Polatuzumab-R-CHP in Previously Untreated Diffuse Large B-Cell Lymphoma: A Retrospective Study

Prediction of PD-L1 and Ki-67 status in primary central nervous system diffuse large B-cell lymphoma by diffusion and perfusion MRI: a preliminary study

ObjectiveTo assess whether diffusion and perfusion MRI derived parameters could non-invasively predict PD-L1 and Ki-67 status in primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL).MethodsWe retrospectively analyzed DWI, DSC-PWI, and morphological MRI (mMRI) in 88 patients with PCNS-DLBCL. The mMRI features were compared using chi-square tests or Fisher exact test. Minimum ADC (ADCmin), mean ADC(ADCmean), relative minimum ADC (rADCmin), relative mean ADC (rADCmean), and relative maximum CBV (rCBVmax) values were compared in PCNS-DLBCL with different molecular status by using the Mann-Whitney U test. The diagnostic performances were evaluated by receiver operating characteristic curves.ResultsPCNS-DLBCL with high PD-L1 expression demonstrated a significantly higher ADCmin value than those with low PD-L1. The ADCmean and rADCmean values were significantly lower in PCNS-DLBCL with high Ki-67 status compared with those in low Ki-67 status. Other ADC, CBV parameters, and mMRI features did not show any association with these molecular statuses The diagnostic efficacy of ADC values in assessing PD-L1 and Ki-67 status was relatively low, with area under the curves (AUCs) values less than 0.7.ConclusionsDWI-derived ADC values can provide some relevant information about PD-L1 and Ki-67 status in PCNS-DLBCL, but may not be sufficient to predict their expression due to the rather low diagnostic performance.

Vision preserving role of radiotherapy in orbital plasmablastic lymphoma

An uncommon but aggressive variant of diffuse large B-cell lymphoma is plasmablastic lymphoma (PBL). Although they primarily involve the gastrointestinal tract, lymph nodes, and oral mucosa of immunocompromised males, orbital presentation is rare. In this article, we report a case of an elderly, immunocompetent gentleman presenting with progressive proptosis, ptosis, and diminished vision of the right eye with a palpable mass in the right upper eyelid. Imaging and biopsy confirmed the rare diagnosis of orbital PBL. After obtaining institutional tumor board concurrence, the patient was delivered 45 Gy external beam radiation therapy followed by six cycles of chemotherapy. Post-therapy, he is in remission with improvement in vision and is currently on maintenance chemotherapy.

Diffuse Large B-Cell Lymphoma of the Bone Recurring in the Skin: A Case Report

Diffuse Large B-Cell Lymphoma of the Bone Recurring in the Skin: A Case Report